Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person brigatinib-resistant ALK mutants don't bind brigatinib

Class:IdFailedReaction:9715356
_displayNamebrigatinib-resistant ALK mutants don't bind brigatinib
_doReleaseTRUE
_timestamp2021-05-04 17:36:29
authored[InstanceEdit:9724129] Rothfels, Karen, 2021-03-22
compartment[Compartment:70101] cytosol
[Compartment:876] plasma membrane
created[InstanceEdit:9715358] Rothfels, Karen, 2021-02-17
disease[Disease:1500689] cancer
edited[InstanceEdit:9725664] Rothfels, Karen, 2021-03-30
entityFunctionalStatus[EntityFunctionalStatus:9714045] loss_of_function of brigatinib-resistant ALK mutants [plasma membrane]
input[ChemicalDrug:9699601] brigatinib [cytosol]
[DefinedSet:9714046] brigatinib-resistant ALK mutants [plasma membrane] [Homo sapiens]
isChimericFALSE
literatureReference[LiteratureReference:9713857] A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib
[LiteratureReference:9713917] Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
[LiteratureReference:9700357] Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma
[LiteratureReference:9700339] Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors
[LiteratureReference:9715259] Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib
[LiteratureReference:9717267] TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors
modified[InstanceEdit:9717353] Rothfels, Karen, 2021-03-08
[InstanceEdit:9724130] Rothfels, Karen, 2021-03-22
[InstanceEdit:9729590] Rothfels, Karen, 2021-04-30
[InstanceEdit:9729893] Rothfels, Karen, 2021-05-04
[InstanceEdit:9830342] Matthews, Lisa, 2023-03-08
namebrigatinib-resistant ALK mutants don't bind brigatinib
normalReaction
releaseDate2021-06-09
reviewed[InstanceEdit:9729891] Inghirami, Giorgio, 2021-05-04
reviewStatus[ReviewStatus:9821382] five stars
species[Species:48887] Homo sapiens
stableIdentifier[StableIdentifier:9715360] R-HSA-9715356.2
summation[Summation:9714031] The following ALK mutants show resistance to brigatinib:

AL...
(hasEvent)[Pathway:9717319] brigatinib-resistant ALK mutants [Homo sapiens]
[Change default viewing format]
No pathways have been reviewed or authored by brigatinib-resistant ALK mutants don't bind brigatinib (9715356)
Follow Reactome